All In Biotech

Drug Trial Radar · NCT05245058

SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jan 21, 2022

Primary completion

Dec 21, 2026

Study completion Dec 21, 2026

Sponsor

Sponsor type
Industry
First posted
Feb 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and tolerability of SPH5030 tablets in subjects with HER2-positive advanced solid tumors

Conditions

  • HER2-positive Advanced Solid Tumors

Interventions

  • SPH5030 tabletsDrug

    SPH5030 tablets orally once or twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT)Time frame: Up to 24 days
  2. Maximum tolerated dose(MTD)Time frame: Up to 24 days
  3. Number of patients with adverse eventsTime frame: Up to 2 years

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, China · Recruiting

  • The second people's hospital of neijiang

    Neijiang, China · Recruiting

  • Tianjin Cancer Hospital Airport Hospital

    Tianjin, China · Recruiting

  • Anhui provincial hospital

    Hefei, Anhui, China · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Guangxi Cancer Hospital

    Nanning, Guangxi, China · Recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Anyang Cancer Hospital

    Anyang, Henan, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • Linyi Cancer Hospital

    Linyi, Shandong, China · Recruiting

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.